View More Recent Stories
-
Structure Therapeutics (GPCR) Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)
-
Morgan Stanley Starts Structure Therapeutics (GPCR) at Overweight
-
Structure Therapeutics (GPCR) Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
-
Structure Therapeutics (GPCR) Appoints Blai Coll as Chief Medical Officer, Ashley Hall as Chief Development Officer
-
Piper Sandler Reiterates Overweight Rating on Structure Therapeutics (GPCR)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)

